| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Grant McFadden | Q88652661 |
| Christopher R. Cogle | Q39395682 | ||
| P2093 | author name string | Masmudur M Rahman | |
| Nancy Y Villa | |||
| P2860 | cites work | Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells | Q74098005 |
| Modification of irradiation injury in mice and guinea pigs by bone marrow injections | Q75832754 | ||
| Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease | Q77320508 | ||
| Role of CD28 in acute graft-versus-host disease | Q77381132 | ||
| Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype | Q77437408 | ||
| Prevention of graft versus host disease by inactivation of host antigen-presenting cells | Q78016071 | ||
| The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality | Q78033315 | ||
| Immunodominance of H60 is caused by an abnormally high precursor T cell pool directed against its unique minor histocompatibility antigen peptide | Q78518647 | ||
| Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients | Q78773723 | ||
| "Secondary disease" of radiation chimeras: a syndrome due to lymphoid aplasia | Q79585828 | ||
| Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses | Q80112113 | ||
| Donor APCs are required for maximal GVHD but not for GVL | Q80402910 | ||
| CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus-host disease | Q80475611 | ||
| The role of the spleen in radiation injury and recovery | Q80702145 | ||
| Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation | Q80884347 | ||
| A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses | Q81357571 | ||
| SMAD3 prevents graft-versus-host disease by restraining Th1 differentiation and granulocyte-mediated tissue damage | Q82674325 | ||
| Graft-versus-host disease | Q83468020 | ||
| Cutaneous GVHD is associated with the expansion of tissue-localized Th1 and not Th17 cells | Q85073883 | ||
| [Allogeneic haematopoietic stem cell transplantation - an overview] | Q87338225 | ||
| Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 | ||
| Randomized double-blind clinical trial comparing clobetasol and dexamethasone for the topical treatment of symptomatic oral chronic graft-versus-host disease | Q87671181 | ||
| Corticosteroids for preventing graft-versus-host disease after allogeneic myeloablative stem cell transplantation | Q24241965 | ||
| Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase–dependent DC functions and regulates experimental graft-versus-host disease in mice | Q24288997 | ||
| The receptor for the cytotoxic ligand TRAIL | Q24310481 | ||
| Chronic graft-versus-host disease: disease biology and novel therapeutic strategies | Q26853286 | ||
| Current and emerging strategies for the prevention of graft-versus-host disease | Q27016541 | ||
| Control of regulatory T cell development by the transcription factor Foxp3 | Q27860489 | ||
| Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases | Q28131652 | ||
| TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis | Q28257134 | ||
| Myxomatosis in Australia and Europe: a model for emerging infectious diseases | Q28259735 | ||
| Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab | Q28274444 | ||
| Host-reactive CD8+ memory stem cells in graft-versus-host disease | Q28281894 | ||
| Transforming growth factor-beta regulation of immune responses | Q28303115 | ||
| LPS responsiveness and neutrophil chemotaxis in vivo require PMN MMP-8 activity | Q28469158 | ||
| Recognition of microorganisms and activation of the immune response | Q29617903 | ||
| Leukocyte migration and graft-versus-host disease | Q30479618 | ||
| Adventures with poxviruses of vertebrates | Q30846908 | ||
| Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. | Q33624804 | ||
| Current and future approaches for control of graft-versus-host disease | Q33642625 | ||
| Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene | Q33781162 | ||
| Pathophysiologic mechanisms of acute graft-vs.-host disease | Q33793177 | ||
| Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus | Q33895494 | ||
| The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation | Q33898254 | ||
| Prodrug-activating systems in suicide gene therapy. | Q33904264 | ||
| The biology of graft-versus-host disease: experimental systems instructing clinical practice | Q33917175 | ||
| In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. | Q33997187 | ||
| Advances in graft-versus-host disease biology and therapy | Q34031916 | ||
| Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity | Q34057782 | ||
| Treatment of chronic graft-versus-host disease with bortezomib | Q34137032 | ||
| Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease | Q34186352 | ||
| Programmed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease | Q42463266 | ||
| Immunology. Orchestrating inflammasomes | Q42569454 | ||
| Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by down-regulating Th1 and Th17. | Q42723911 | ||
| Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. | Q42794018 | ||
| The addition of tumor necrosis factor plus beta interferon induces a novel synergistic antiviral state against poxviruses in primary human fibroblasts | Q43215263 | ||
| Engineered regulatory T cells prevent graft-versus-host disease while sparing the graft-versus-leukemia effect after bone marrow transplantation | Q43494585 | ||
| Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease | Q43733290 | ||
| Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality | Q43819629 | ||
| Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects | Q43852100 | ||
| Treatment of post-bone marrow transplant acute graft-versus-host disease with a rationally designed JAK3 inhibitor | Q44186553 | ||
| CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation | Q44408941 | ||
| Proteasome inhibition profoundly affects activated human B cells. | Q44467702 | ||
| Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia | Q44499780 | ||
| 2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders | Q44675985 | ||
| Control of mouse graft-versus-host disease following allogeneic bone marrow transplantation by blocking the CD28/B7 signaling pathway with lentiviral vector-mediated RNA interference | Q44699892 | ||
| Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease | Q45111052 | ||
| HLA-haploidentical stem cell transplantation after removal of αβ+ T and B cells in children with nonmalignant disorders | Q45120298 | ||
| Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings | Q45132133 | ||
| Differentiation and expansion of T cells with regulatory function from human peripheral lymphocytes by stimulation in the presence of TGF-{beta}. | Q45232006 | ||
| Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes | Q45888667 | ||
| The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis | Q46549173 | ||
| A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation | Q46570946 | ||
| Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis | Q46790735 | ||
| Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome | Q47359749 | ||
| Prognostic value of apoptotic cells and infiltrating neutrophils in graft-versus-host disease of the gastrointestinal tract in humans: TNF and Fas expression | Q47735710 | ||
| Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism | Q47745301 | ||
| The biology of graft-versus-host reactions | Q47809350 | ||
| PKC theta cooperates with PKC alpha in alloimmune responses of T cells in vivo | Q48030302 | ||
| Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. | Q37275902 | ||
| Notch signaling in hematopoietic cell transplantation and T cell alloimmunity. | Q37325713 | ||
| Recognizing and managing chronic graft-versus-host disease | Q37346706 | ||
| Treatment and management of graft-versus-host disease: improving response and survival | Q37371836 | ||
| Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice | Q37387820 | ||
| Acute graft-versus-host disease: from the bench to the bedside | Q37420496 | ||
| PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice | Q37452305 | ||
| Costimulatory pathways in transplantation: challenges and new developments. | Q37474958 | ||
| Hemopoietic stem cell transplantation using mouse bone marrow and spleen cells fractionated by lectins | Q37589086 | ||
| The role of B cells in the pathogenesis of graft-versus-host disease | Q37596195 | ||
| New perspectives on the biology of acute GVHD. | Q37641063 | ||
| Physiological and pathological roles for microRNAs in the immune system | Q37680666 | ||
| Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation | Q37685142 | ||
| Genetically engineered T-cells expressing a ganciclovir-sensitive HSV-tk suicide gene for the prevention of GvHD. | Q37737174 | ||
| Intervention with costimulatory pathways as a therapeutic approach for graft-versus-host disease | Q37785736 | ||
| Alemtuzumab for the prevention and treatment of graft-versus-host disease | Q37849208 | ||
| Rituximab for prevention and treatment of graft-versus-host disease | Q37872661 | ||
| Danger signals activating innate immunity in graft-versus-host disease | Q37875779 | ||
| B cell homeostasis and the development of chronic graft-versus-host disease: implications for B cell-depleting therapy | Q37899200 | ||
| Oncolytic virotherapy | Q38025263 | ||
| Biology of graft-versus-host responses: recent insights | Q38071746 | ||
| Thinking out of the box--new approaches to controlling GVHD. | Q38175862 | ||
| State-of-the-art acute and chronic GVHD treatment | Q38416376 | ||
| Myxoma and vaccinia viruses bind differentially to human leukocytes | Q39198482 | ||
| Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts | Q39244446 | ||
| Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro | Q39395568 | ||
| Pharmacological manipulation of the akt signaling pathway regulates myxoma virus replication and tropism in human cancer cells | Q39610261 | ||
| The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status | Q39703425 | ||
| Myxoma and vaccinia viruses exploit different mechanisms to enter and infect human cancer cells. | Q39723487 | ||
| Memory CD4+ T cells do not induce graft-versus-host disease | Q39778135 | ||
| Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3. | Q40055892 | ||
| Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. | Q40404351 | ||
| Induction of antigen-specific tolerance to bone marrow allografts with CD4+CD25+ T lymphocytes | Q40530227 | ||
| Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease | Q40627364 | ||
| FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. | Q40669703 | ||
| Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells | Q41052462 | ||
| Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus | Q42144185 | ||
| Prevention of EBV lymphoma development by oncolytic myxoma virus in a murine xenograft model of post-transplant lymphoproliferative disease. | Q42150554 | ||
| Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib | Q34332019 | ||
| Virotherapy using myxoma virus prevents lethal graft-versus-host disease following xeno-transplantation with primary human hematopoietic stem cells. | Q34384975 | ||
| Th17/Treg ratio in human graft-versus-host disease. | Q34403757 | ||
| Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. | Q34420372 | ||
| Recent advances in the management of graft-versus-host disease | Q34428890 | ||
| Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial | Q34446176 | ||
| Improving the safety of cell therapy with the TK-suicide gene | Q34477411 | ||
| CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease | Q34525987 | ||
| Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease. | Q34568892 | ||
| Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. | Q34574890 | ||
| Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. | Q34577019 | ||
| Cytolytic pathways in haematopoietic stem-cell transplantation | Q34632083 | ||
| Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. | Q34684038 | ||
| Sequential activation of inflammatory signaling pathways during graft-versus-host disease (GVHD): early role for STAT1 and STAT3. | Q34703720 | ||
| Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria | Q34707280 | ||
| Blockade of LIGHT/LTbeta and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease | Q34788330 | ||
| Myxoma virus protein M029 is a dual function immunomodulator that inhibits PKR and also conscripts RHA/DHX9 to promote expanded host tropism and viral replication | Q34819569 | ||
| HDAC inhibition and graft versus host disease | Q35016985 | ||
| Contrasting alloreactive CD4+ and CD8+ T cells: there's more to it than MHC restriction | Q35072094 | ||
| Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets | Q35158939 | ||
| Aberrant B-cell homeostasis in chronic GVHD | Q35171251 | ||
| Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-beta | Q35223463 | ||
| Oncolytic Poxviruses | Q35234349 | ||
| Absence of Stat1 in donor CD4⁺ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice | Q35572384 | ||
| Oncolytic virotherapy for hematological malignancies | Q35692095 | ||
| Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells | Q35724025 | ||
| Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity | Q35848453 | ||
| Absence of inducible costimulator on alloreactive T cells reduces graft versus host disease and induces Th2 deviation | Q35848468 | ||
| Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. | Q35917157 | ||
| Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review | Q35953264 | ||
| Manipulating the bioenergetics of alloreactive T cells causes their selective apoptosis and arrests graft-versus-host disease | Q35998783 | ||
| Regulation of acute graft-versus-host disease by microRNA-155. | Q36010229 | ||
| First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation | Q36113205 | ||
| Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). | Q50782599 | ||
| L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. | Q50796687 | ||
| Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. | Q50798708 | ||
| Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. | Q50911359 | ||
| Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor) | Q51608296 | ||
| Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia. | Q51961297 | ||
| Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease. | Q51994114 | ||
| Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. | Q53313339 | ||
| Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells | Q54502944 | ||
| Allogeneic marrow grafting for treatment of aplastic anemia. | Q54602596 | ||
| A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. | Q55042980 | ||
| Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy | Q56777948 | ||
| CD4+CD25high regulatory cells in human peripheral blood | Q56905059 | ||
| Acute graft-versus-host reaction can be aborted by blockade of costimulatory molecules | Q56909368 | ||
| In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice | Q56909694 | ||
| Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia | Q58865943 | ||
| A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients | Q59511999 | ||
| Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here? | Q61651652 | ||
| A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation | Q66829333 | ||
| Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease | Q68882743 | ||
| Graft failures after T cell depleted marrow transplants for leukemia: clinical and in vitro characteristics | Q70043806 | ||
| Immunological reconstitution of sex-linked lymphopenic immunological deficiency | Q70099373 | ||
| Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease | Q70837443 | ||
| Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation | Q71929801 | ||
| Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation | Q72419264 | ||
| Allogeneic bone marrow transplantation using stem cells fractionated by lectins: VI, in vitro analysis of human and monkey bone marrow cells fractionated by sheep red blood cells and soybean agglutinin | Q72445822 | ||
| Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells | Q72488507 | ||
| Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice | Q72776658 | ||
| Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients | Q73509907 | ||
| Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines | Q73894705 | ||
| Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model | Q74097996 | ||
| Life-threatening graft-vs-host disease | Q36129049 | ||
| Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab | Q36219690 | ||
| STAT3 transcription factor promotes instability of nTreg cells and limits generation of iTreg cells during acute murine graft-versus-host disease. | Q36231545 | ||
| Acute graft-versus-host disease. | Q36257607 | ||
| Acute graft versus host disease: pathophysiology, risk factors, and prevention strategies | Q36259010 | ||
| Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow | Q36342244 | ||
| Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease | Q36366324 | ||
| Pathophysiology of graft-versus-host disease | Q36368101 | ||
| The clinical spectrum of acute graft-versus-host disease | Q36368111 | ||
| Prophylaxis and treatment of acute graft-versus-host disease | Q36368115 | ||
| Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation | Q36370863 | ||
| PKCtheta signals activation versus tolerance in vivo | Q36402354 | ||
| Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease | Q36445956 | ||
| Induction of tumor immunity following allogeneic stem cell transplantation | Q36490755 | ||
| Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells | Q36565516 | ||
| CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse | Q36608689 | ||
| Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. | Q36639793 | ||
| Immunobiology of allogeneic hematopoietic stem cell transplantation | Q36665305 | ||
| T cell-directed therapies: lessons learned and future prospects | Q36688370 | ||
| Myxoma virus in the European rabbit: interactions between the virus and its susceptible host | Q36734188 | ||
| Novel strategies for the treatment and diagnosis of graft-versus-host-disease | Q36750653 | ||
| Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease | Q36843812 | ||
| Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey | Q36862931 | ||
| Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer | Q36922264 | ||
| The role of cell signaling in poxvirus tropism: the case of the M-T5 host range protein of myxoma virus | Q36955701 | ||
| Searching for alternative hematopoietic stem cell donors for pediatric patients | Q37033846 | ||
| IL-17 contributes to CD4-mediated graft-versus-host disease | Q37071147 | ||
| Oncolytic myxoma virus: the path to clinic | Q37126088 | ||
| Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa | Q37157967 | ||
| The Nlrp3 inflammasome regulates acute graft-versus-host disease | Q37194967 | ||
| Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice | Q37215167 | ||
| The biology and therapeutic potential of natural regulatory T-cells in the bone marrow transplant setting | Q37228646 | ||
| Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality | Q37263177 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | graft-versus-host disease | Q1194520 |
| oncolytic virotherapy | Q73217729 | ||
| P304 | page(s) | 85 | |
| P577 | publication date | 2016-03-01 | |
| 2016-03-22 | |||
| P1433 | published in | Viruses | Q7935305 |
| P1476 | title | Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies | |
| P478 | volume | 8 |
| Q51770637 | Changes in body composition in children with acute graft-versus-host disease within the first 100 days after hematopoietic stem cell transplantation. | cites work | P2860 |
Search more.